Key result
A 67-year-old woman experienced acute stent thrombosis 46 hours after bare metal stent implantation due to complete clopidogrel resistance despite a loading dose.
Case Report (n=1)
This case highlights the clinical consequences of clopidogrel resistance, emphasizing the potential need for alternative P2Y12 inhibitors like prasugrel in non-responders.
Answers are grounded in this paper and cite their sources.
Clopidogrel resistance linked to acute stent thrombosis in one case; hypothesis-generating and should not change practice.
Every year, millions of people undergo percutaneous coronary intervention (PCI) with intracoronary stent implantation. A patient from the PRAGUE-8 trial (Optimal pre-PCI clopidogrel loading: 600 mg before every coronary angiography vs. 600 mg in the cath-lab only for PCI patients) is described who suffered from acute stent thrombosis. This patient did not have any relevant inhibition of platelet activation even after the 600 mg dose of clopidogrel. Dose uptitration would have been ineffective. New P2Y12 receptor inhibitors are desperately needed. In the light of recently published data, the use of prasugrel may be considered as an alternative.
No takes yet. Share an insight, caveat, or question.
Moťovská et al. (2009) conducted a case report in Clopidogrel resistance and acute stent thrombosis (n=1). Clopidogrel was evaluated on Platelet reactivity (VASP phosphorylation). A 67-year-old woman experienced acute stent thrombosis 46 hours after bare metal stent implantation due to complete clopidogrel resistance despite a loading dose.
Synapse has enriched 10 related papers. Consider them for comparative context: